Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2106 After a Single Intravenous or Subcutaneous Administration of SHR-2106 in Healthy Subjects

NCT05948059 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05948059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05948059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2106 After a Single Intravenous or Subcutaneous Administration of SHR-2106 in Healthy Subjects
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2023
Completion date
May 10, 2024
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation